Obicetrapib: The CETP Inhibitor That Came Back From the Dead

Every few years a drug shows up that makes the lipid crowd lose their minds, and the enhanced community immediately asks the same question: can this undo what my cycle does to my bloodwork? Obicetrapib is that drug right now. Here’s the honest version, including the parts that don’t help the story.

What obicetrapib actually is

Cholesteryl ester transfer protein (CETP) shuttles cholesteryl esters out of HDL particles and into ApoB-containing particles — LDL and VLDL — in exchange for triglycerides. Block it and cholesterol stays in HDL instead of ending up in LDL. HDL-C goes up dramatically, LDL-C goes down.

Obicetrapib is a low-dose, highly selective oral CETP inhibitor dosed at 10 mg once daily, developed by NewAmsterdam Pharma with European commercialization rights licensed to the Menarini Group. It is being studied as an add-on to statins, not a replacement.

Why the entire class got buried — twice

If you don’t understand why CETP inhibition was declared dead, you can’t judge whether it’s actually alive.

Torcetrapib (Pfizer). ILLUMINATE was stopped early because torcetrapib increased cardiovascular events and all-cause mortality despite raising HDL-C substantially. It also raised blood pressure. That looked like a class indictment for years. It wasn’t — torcetrapib stimulates aldosterone and cortisol production through a mechanism independent of CETP inhibition. A molecule-specific off-target problem, not a pathway problem.

Dalcetrapib (Roche). A weak CETP modulator. dal-OUTCOMES was stopped for futility. It barely moved LDL-C, which in hindsight is the whole explanation.

Evacetrapib (Lilly). ACCELERATE was also stopped for futility, despite good-looking lipid changes.

Anacetrapib (Merck). The one that gets forgotten. REVEAL randomized 30,449 patients on atorvastatin and found a 9% proportional reduction in major coronary events (rate ratio 0.91, 95% CI 0.85–0.97, p=0.004) over a median 4.1 years. That is a positive outcomes trial. Merck declined to commercialize anyway — the benefit was modest, and anacetrapib accumulated in adipose tissue.

The honest read is not “CETP inhibition doesn’t work.” It’s: chasing HDL-C was the wrong hypothesis, one molecule was toxic for reasons unrelated to the target, two were too weak, and the one that lowered LDL meaningfully produced a real but modest outcome benefit.

What changed: the ApoB reframe

Nobody is selling CETP inhibition as an HDL drug anymore. It’s being sold as an LDL/ApoB drug that happens to raise HDL.

The strongest supporting evidence isn’t a trial — it’s genetics. A 2017 JAMA Mendelian randomization analysis by Ference and colleagues examined genetic variants in CETP alongside HMGCR variants (the statin target) across 102,837 participants. Combined exposure produced discordant reductions in LDL-C and ApoB — and cardiovascular risk tracked the change in ApoB, not the change in LDL-C.

Translation: lifelong lower CETP activity does appear to lower cardiovascular risk, but the LDL-C number overstates the benefit. The ApoB number is the honest one. Hold that thought.

The Phase 3 lipid data — the real numbers

Three pivotal trials have reported. All are lipid-endpoint trials, all placebo-controlled, all on top of maximally tolerated background therapy.

Trial	Population / n	Primary result (day 84)	Other reported changes
BROADWAY (NEJM, 2025)	ASCVD and/or HeFH, n=2,530, 10 mg vs placebo 2:1, 365 days	LDL-C least-squares mean change −29.9% with obicetrapib vs +2.7% with placebo (P<0.001)	Lp(a) between-group difference −33.5% (baseline mean 39 nmol/L). Exploratory MACE 4.2% vs 5.2% (HR 0.79; 95% CI 0.54–1.15) — underpowered. Total adverse events 59.7% vs 60.8%.
BROOKLYN (Nature Medicine, 2026)	Heterozygous FH, n=354, LDL-C ≥70 mg/dL on max tolerated therapy	LDL-C placebo-adjusted −36.3% (95% CI −42.2 to −30.4, P<0.0001)	ApoB −24.4%, non-HDL-C −34.5%, Lp(a) −45.9%, HDL-C +138.7% (all placebo-adjusted, day 84)
TANDEM (Lancet, 2025)	ASCVD/high-risk and/or HeFH, n=407, four arms	Fixed-dose obicetrapib 10 mg + ezetimibe 10 mg: LDL-C −48.6% vs placebo (P<0.001)	vs ezetimibe alone −27.9%; vs obicetrapib alone −16.8%; obicetrapib monotherapy vs placebo −31.9%

A pooled analysis across the three trials, reported by the sponsor at EAS 2025, found a median placebo-adjusted 45% reduction in Lp(a) at 12 weeks in patients with baseline Lp(a) between 50 and 150 nmol/L. That is genuinely interesting, because Lp(a) is largely genetically fixed and no approved oral drug moves it. Tolerability across the program has been unremarkable — adverse event rates comparable to placebo, no torcetrapib-type blood-pressure signal.

The caveat that should govern how you read all of the above

Look again at BROOKLYN: LDL-C down 36.3%, ApoB down 24.4%. That gap is not noise. It is the predicted consequence of CETP inhibition — you shift cholesterol cargo between particles, so the cholesterol-mass measurement (LDL-C) drops more than the particle-count measurement (ApoB). The Mendelian randomization work says risk follows particle count.

If you assume this drug delivers PCSK9-inhibitor-grade risk reduction because the LDL-C percentage looks similar, you’re making an error the genetics already warned you about.

PREVAIL: the trial that decides everything

PREVAIL is the cardiovascular outcomes trial — over 9,500 patients with established ASCVD, obicetrapib 10 mg vs placebo on background lipid-lowering therapy, with MACE as the primary endpoint. Enrollment completed in April 2024. The sponsor has stated an interim analysis is planned for Q4 2026 with results expected in Q1 2027, and if the trial does not stop early for efficacy, completion is anticipated by the end of 2027.

Until PREVAIL reports, everything above is surrogate-endpoint data. LDL-lowering is not the same thing as proven outcome benefit. Evacetrapib lowered LDL-C and failed on outcomes. That’s not a hypothetical failure mode — it’s a documented one, in this exact drug class.

Why this matters specifically to enhanced lifters

Oral 17-alpha-alkylated androgens do something to lipoproteins that is qualitatively different from injectable testosterone, and it’s been documented since the 1980s.

Thompson and colleagues ran a crossover study in JAMA in 1989: 11 male weightlifters, six weeks each on oral stanozolol 6 mg/day versus intramuscular testosterone enanthate 200 mg/week. Stanozolol cut HDL-C by 33% and the HDL2 subfraction by 71%. ApoA-I dropped 40%. LDL-C went up 29%. On injectable testosterone: HDL-C down only 9%, ApoA-I down 8%, LDL-C down 16%. Same androgen class, opposite lipid outcome — driven largely by hepatic lipase upregulation from first-pass oral exposure.

This isn’t just a bloodwork curiosity. Baggish and colleagues imaged 140 male weightlifters in Circulation in 2017 — 86 with ≥2 years cumulative AAS use, 54 non-users. Users showed reduced left ventricular ejection fraction (52±11% vs 63±8%) and accelerated coronary plaque. That’s structure and disease, not a number on a lab slip.

So the appeal of a CETP inhibitor here is obvious: a drug that raises HDL-C by triple digits and drops LDL-C by a third looks like a direct antidote. I understand the appeal. It’s premature reasoning for three reasons:

• Zero trial data in this population. Every obicetrapib trial enrolled ASCVD or FH patients on statins. Nobody has studied a 240-pound lifter running orals.
• The HDL number is the least meaningful number in the dataset. Raising HDL-C pharmacologically has failed repeatedly. A drug that “fixes” crashed HDL on paper has not been shown to fix the risk.
• It doesn’t touch the cause. Hepatic lipase induction, hypertension, LV remodeling, hematocrit — a CETP inhibitor addresses none of it.

What to actually do right now

This part is real, available, and doesn’t depend on a trial that hasn’t read out:

• ApoB, not LDL-C. ApoB counts atherogenic particles and survives every discordance analysis. Cheap and widely available — the single most valuable addition to most lifters’ bloodwork panel.
• Lp(a), once. Largely genetically determined, so one lifetime measurement mostly does it. If it’s high, that’s a permanent multiplier on everything else. More in this breakdown for enhanced lifters.
• Full lipid panel on and off cycle. The delta tells you what your specific compounds do to you. Interpretation in reading the markers that matter.
• An honest audit of your oral usage. The 1989 data is unambiguous: route of administration matters more than androgenic potency for lipid damage. Reducing oral exposure is the best-evidenced intervention available to you today, and it costs nothing. Context in the hormone protocol discussion.
• Talk to a physician about proven ApoB-lowering therapy. Statins, ezetimibe and PCSK9 inhibitors all have outcomes data. Obicetrapib does not — yet.

Where this lands

Obicetrapib is the most interesting lipid drug in late-stage development, and the CETP class was buried prematurely. The Lp(a) effect in an oral pill is legitimately novel. But it is investigational, not available by general prescription, its ApoB effect is meaningfully smaller than its LDL-C headline, and its outcomes trial has not reported.

Bet on the measurement, not the molecule. ApoB and Lp(a) on your next panel will do more for you than any amount of speculation about a drug that may or may not ship. Nail your nutrition, know your numbers, and let PREVAIL tell us whether this one earns its place.

FAQ

Is obicetrapib approved and can I get a prescription for it?

No. Obicetrapib is investigational and is not approved for general prescription. Regulatory decisions from European, UK and Swiss authorities were anticipated in the second half of 2026, and there is no US approval. It is not something to seek out through unofficial channels.

Does obicetrapib lower ApoB as much as it lowers LDL cholesterol?

No, and this is the most important nuance in the data. In the BROOKLYN trial, obicetrapib reduced LDL-C by 36.3% placebo-adjusted but ApoB by 24.4%. Mendelian randomization work published in JAMA in 2017 found that when CETP variants produce discordant LDL-C and ApoB changes, cardiovascular risk tracks ApoB rather than LDL-C.

Would a CETP inhibitor fix the HDL crash caused by oral androgens?

On paper it would raise the HDL-C number substantially, but no trial has studied obicetrapib in androgen users, and pharmacologically raising HDL-C has repeatedly failed to translate into risk reduction. It would also do nothing about hepatic lipase induction, blood pressure, or cardiac remodeling associated with anabolic steroid use.

Why did torcetrapib fail if obicetrapib is working?

Torcetrapib increased cardiovascular events and all-cause mortality in the ILLUMINATE trial, and also raised blood pressure. The cause was traced to off-target stimulation of aldosterone and cortisol production, a mechanism independent of CETP inhibition. That failure was molecule-specific rather than a property of the pathway.

What should an enhanced lifter measure right now instead of waiting on this drug?

Order ApoB rather than relying on LDL-C alone, get Lp(a) measured once since it is largely genetically fixed, run a lipid panel both on and off cycle to see your personal delta, and honestly audit oral 17-alpha-alkylated compound use, since route of administration drives most of the lipid damage.

Medical disclaimer: This article is for informational and educational purposes only and is not medical advice; discuss any lipid testing or treatment decision with a qualified physician.